View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBioservo Technologies 향후 성장Future 기준 점검 2/6Bioservo Technologies의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Medical Equipment 이익 성장22.2%매출 성장률69.3%향후 자기자본이익률6.36%애널리스트 커버리지Low마지막 업데이트08 Nov 2023최근 향후 성장 업데이트Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.모든 업데이트 보기Recent updates공시 • Jan 05Bioservo to Be Delisted from Nasdaq First NorthNasdaq has decided to approve Bioservo Technologies AB (publ)'s application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024.공시 • Dec 15Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth MarketAt the extraordinary general meeting held in Bioservo Technologies AB (publ) (the "Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator. Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press release shortly after the Company has received confirmation from Nasdaq First North.New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (200% increase in shares outstanding). Market cap is less than US$10m (kr5.32m market cap, or US$509.5k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr52m). Revenue is less than US$5m (kr12m revenue, or US$1.1m).Reported Earnings • Nov 08Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.47m (up 31% from 3Q 2022). Net loss: kr9.76m (loss narrowed 8.9% from 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.공시 • Sep 27Bioservo Technologies AB (publ) Appoints Annika Rydgård as A New Member of the Management TeamBioservo Technologies AB (publ) announced appointment of Annika Rydgård as a new member of the management team, responsible for clinical projects and Market Access.Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.45m (down 72% from 2Q 2022). Net loss: kr11.9m (loss widened 1.1% from 2Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden.공시 • Jul 07Bioservo Technologies AB (Publ) Announces Chief Financial Officer ChangesBioservo Technologies AB (publ) announced that the company has contracted Michael Forss as new interim CFO and member of the management team. Michael succeeds Madeleine Börjesson as CFO and will take up the position on July 7, 2023. Michael has a background as an auditor and partner at EY with long and valuable experience of public companies in an international environment. Since 2019, Michael works in his own consulting company with advice in financial accounting, reporting and business management. Bioservo would like to take the opportunity to thank resigning CFO Madeleine Börjesson for her valuable contribution to the company and wish her all the best in the future.New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 350% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Market cap is less than US$10m (kr55.8m market cap, or US$5.24m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).Reported Earnings • Apr 26First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr4.94m (up 18% from 1Q 2022). Net loss: kr9.38m (loss narrowed 23% from 1Q 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Feb 22Full year 2022 earnings released: kr2.66 loss per share (vs kr2.09 loss in FY 2021)Full year 2022 results: kr2.66 loss per share (further deteriorated from kr2.09 loss in FY 2021). Revenue: kr14.8m (up 41% from FY 2021). Net loss: kr50.5m (loss widened 46% from FY 2021). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.Reported Earnings • Nov 20Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr3.42m (down 39% from 3Q 2021). Net loss: kr10.7m (loss widened 70% from 3Q 2021). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Sweden.Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.Reported Earnings • Sep 01Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.15m (up 403% from 2Q 2021). Net loss: kr11.8m (loss widened 8.2% from 2Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 146% growth forecast for the Medical Equipment industry in Sweden.Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr4.20m (up 91% from 1Q 2021). Net loss: kr12.1m (loss widened 35% from 1Q 2021). Over the next year, revenue is forecast to grow 113%, compared to a 104% growth forecast for the industry in Sweden.Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.83 loss per share (down from kr1.82 loss in FY 2020). Revenue: kr11.9m (down 16% from FY 2020). Net loss: kr34.7m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 1.6%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 10Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr5.59m (up 54% from 3Q 2020). Net loss: kr6.30m (loss widened 8.5% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 02Chairman of the Board recently bought kr149k worth of stockOn the 31st of August, Anders Lundmark bought around 13k shares on-market at roughly kr11.70 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.분석 기사 • Sep 01Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Reported Earnings • Aug 13Second quarter 2021 earnings releasedThe company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.02m (down 76% from 2Q 2020). Net loss: kr10.9m (loss widened 125% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • May 05First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr2.19m (up 25% from 1Q 2020). Net loss: kr8.99m (loss widened 19% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.분석 기사 • Apr 11Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...Is New 90 Day High Low • Mar 11New 90-day low: kr13.80The company is down 21% from its price of kr17.50 on 11 December 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.Reported Earnings • Feb 25Full year 2020 earnings released: kr1.82 loss per share (vs kr2.35 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr11.7m (down 51% from FY 2019). Net loss: kr26.3m (loss widened 13% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Dec 28New 90-day high: kr17.65The company is up 42% from its price of kr12.40 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.분석 기사 • Dec 27We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Is New 90 Day High Low • Dec 11New 90-day high: kr14.70The company is up 27% from its price of kr11.60 on 11 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.Is New 90 Day High Low • Nov 24New 90-day low: kr10.35The company is down 22% from its price of kr13.35 on 26 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: kr11.35The company is down 9.0% from its price of kr12.50 on 28 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period.이익 및 매출 성장 예측OM:BIOS - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202558N/A26112/31/202432N/A-15-13112/31/202315N/A-39-3819/30/202312-47-52-51N/A6/30/202311-48-51-51N/A3/31/202315-48-52-51N/A12/31/202214-50-52-51N/A9/30/202215-43-48-46N/A6/30/202217-39-40-38N/A3/31/202213-38-41-39N/A12/31/202111-35-36-34N/A9/30/20217-34-30-29N/A6/30/20215-34-24-23N/A3/31/202110-28-19-18N/A12/31/202014-26-18-17N/A9/30/202022-25-26-25N/A6/30/202023-24-24-23N/A3/31/202025-25-25-24N/A12/31/201924-23-27-26N/A9/30/201923-27-22-21N/A6/30/201921-28-32-29N/A3/31/201917-27-22-19N/A12/31/201816-28-22-17N/A9/30/201815-23-22-17N/A6/30/201814-21-18-13N/A3/31/201812-22-29-23N/A12/31/201712-19-22-16N/A9/30/201711-17-21-15N/A6/30/201711-16N/A-14N/A3/31/201712-12N/A-9N/A12/31/201611-13N/A-13N/A12/31/201511-7N/AN/AN/A12/31/20148-4N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: BIOS 의 예상 수익 증가율이 절약률(0.8%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: BIOS 의 수익이 Swedish 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: BIOS 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: BIOS 의 수익(연간 69.3%)이 Swedish 시장(연간 0.02%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: BIOS 의 수익(연간 69.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: BIOS의 자본 수익률은 3년 후 6.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/01/12 03:56종가2024/01/12 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioservo Technologies AB (publ)는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Mats HyttingeCarlsquare ABMats HyttingeRedeye
Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.
공시 • Jan 05Bioservo to Be Delisted from Nasdaq First NorthNasdaq has decided to approve Bioservo Technologies AB (publ)'s application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024.
공시 • Dec 15Bioservo Applies for Delisting of its Shares from Nasdaq First North Growth MarketAt the extraordinary general meeting held in Bioservo Technologies AB (publ) (the "Company") on December 14, 2023, it was decided that the Company would enter into voluntary liquidation in accordance with Chapter 25, Section 3 of the Companies Act, effective from the time of the Companies Registration Office's appointment of a liquidator. Against this background, the Company has, on behalf of the Board of Directors, applied for delisting of the Company's shares from Nasdaq First North Growth Market. The last day of trading in the Company's shares will be announced through a separate press release shortly after the Company has received confirmation from Nasdaq First North.
New Risk • Nov 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (200% increase in shares outstanding). Market cap is less than US$10m (kr5.32m market cap, or US$509.5k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr52m). Revenue is less than US$5m (kr12m revenue, or US$1.1m).
Reported Earnings • Nov 08Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: kr4.47m (up 31% from 3Q 2022). Net loss: kr9.76m (loss narrowed 8.9% from 3Q 2022). Revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Medical Equipment industry in Sweden.
공시 • Sep 27Bioservo Technologies AB (publ) Appoints Annika Rydgård as A New Member of the Management TeamBioservo Technologies AB (publ) announced appointment of Annika Rydgård as a new member of the management team, responsible for clinical projects and Market Access.
Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: kr1.45m (down 72% from 2Q 2022). Net loss: kr11.9m (loss widened 1.1% from 2Q 2022). Revenue is forecast to grow 63% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden.
공시 • Jul 07Bioservo Technologies AB (Publ) Announces Chief Financial Officer ChangesBioservo Technologies AB (publ) announced that the company has contracted Michael Forss as new interim CFO and member of the management team. Michael succeeds Madeleine Börjesson as CFO and will take up the position on July 7, 2023. Michael has a background as an auditor and partner at EY with long and valuable experience of public companies in an international environment. Since 2019, Michael works in his own consulting company with advice in financial accounting, reporting and business management. Bioservo would like to take the opportunity to thank resigning CFO Madeleine Börjesson for her valuable contribution to the company and wish her all the best in the future.
New Risk • Jun 17New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 350% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr52m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Market cap is less than US$10m (kr55.8m market cap, or US$5.24m). Minor Risk Revenue is less than US$5m (kr15m revenue, or US$1.4m).
Reported Earnings • Apr 26First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: kr4.94m (up 18% from 1Q 2022). Net loss: kr9.38m (loss narrowed 23% from 1Q 2022). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Feb 22Full year 2022 earnings released: kr2.66 loss per share (vs kr2.09 loss in FY 2021)Full year 2022 results: kr2.66 loss per share (further deteriorated from kr2.09 loss in FY 2021). Revenue: kr14.8m (up 41% from FY 2021). Net loss: kr50.5m (loss widened 46% from FY 2021). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Nov 20Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr3.42m (down 39% from 3Q 2021). Net loss: kr10.7m (loss widened 70% from 3Q 2021). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Sweden.
Price Target Changed • Nov 16Price target decreased to kr8.00Down from kr16.00, the current price target is provided by 1 analyst. New target price is 242% above last closing price of kr2.34. Stock is down 79% over the past year. The company posted a net loss per share of kr2.09 last year.
Reported Earnings • Sep 01Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr5.15m (up 403% from 2Q 2021). Net loss: kr11.8m (loss widened 8.2% from 2Q 2021). Over the next year, revenue is forecast to grow 59%, compared to a 146% growth forecast for the Medical Equipment industry in Sweden.
Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr4.20m (up 91% from 1Q 2021). Net loss: kr12.1m (loss widened 35% from 1Q 2021). Over the next year, revenue is forecast to grow 113%, compared to a 104% growth forecast for the industry in Sweden.
Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.83 loss per share (down from kr1.82 loss in FY 2020). Revenue: kr11.9m (down 16% from FY 2020). Net loss: kr34.7m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 1.6%. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 10Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr5.59m (up 54% from 3Q 2020). Net loss: kr6.30m (loss widened 8.5% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 02Chairman of the Board recently bought kr149k worth of stockOn the 31st of August, Anders Lundmark bought around 13k shares on-market at roughly kr11.70 per share. This was the largest purchase by an insider in the last 3 months. This was Anders' only on-market trade for the last 12 months.
분석 기사 • Sep 01Is Bioservo Technologies (STO:BIOS) In A Good Position To Deliver On Growth Plans?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Reported Earnings • Aug 13Second quarter 2021 earnings releasedThe company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: kr1.02m (down 76% from 2Q 2020). Net loss: kr10.9m (loss widened 125% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • May 05First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr2.19m (up 25% from 1Q 2020). Net loss: kr8.99m (loss widened 19% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
분석 기사 • Apr 11Bioservo Technologies (STO:BIOS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Is New 90 Day High Low • Mar 11New 90-day low: kr13.80The company is down 21% from its price of kr17.50 on 11 December 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period.
Reported Earnings • Feb 25Full year 2020 earnings released: kr1.82 loss per share (vs kr2.35 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr11.7m (down 51% from FY 2019). Net loss: kr26.3m (loss widened 13% from FY 2019). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Dec 28New 90-day high: kr17.65The company is up 42% from its price of kr12.40 on 29 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period.
분석 기사 • Dec 27We're Not Very Worried About Bioservo Technologies' (STO:BIOS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Is New 90 Day High Low • Dec 11New 90-day high: kr14.70The company is up 27% from its price of kr11.60 on 11 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Nov 24New 90-day low: kr10.35The company is down 22% from its price of kr13.35 on 26 August 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: kr11.35The company is down 9.0% from its price of kr12.50 on 28 July 2020. The Swedish market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 3.0% over the same period.